ODAC To Consider Whether Genasense Requires Additional Study For Melanoma Indication
This article was originally published in The Pink Sheet Daily
Aventis/Genta Genasense for advanced malignant melanoma failed to show an overall survival benefit but appeared to extend progression-free survival. FDA tells committee that progression-free survival has not historically served as basis for approval.
You may also be interested in...
Amended application includes 50 mg and 100 mg dosage forms, which are used in multiple myeloma.
A draft agreement between industry and FDA that would assess user fees for "advisory review" of broadcast direct-to-consumer ads prior to initial public dissemination had its genesis in the Pharmaceutical Research & Manufacturers of America's DTC guiding principles
Sepracor's television ads for its sleep aid Lunesta create brand recognition better than other new prescription drug direct-to-consumer ads, according to an analysis performed by IAG Research